Amro Albanna ( 00:03 ): All right, so we'll go ahead and just wait for, I guess, five or 10 seconds here in case you are listening. I am seeing some of the attendees joining and let's see, more people are joining. Thank

Amro Albanna (00:03):

All right, so we'll go ahead and just wait

for, I guess, five or 10 seconds here in case you are listening. I am seeing some of the attendees joining and let's see, more people

are joining. Thank you. Thank you all for joining. Good morning. Good afternoon. My name is Amro Albanna. I am the co-founder and CEO

of Aditxt. And today, I have Jeff Ramson, who has been joining me for the past few sessions as we continue to provide updates on Aditxt.

So Jeff, as we always do, please go ahead and

just quickly introduce yourself. I know we do this over and over and over again, but it's really important because you never know

who's joining us for the first time. So please go ahead and introduce yourself.

Jeff Ramson (00:50):

Happy to. Jeff Ramson, CEO of PCG Advisory. I'm

also working with Amro on corporate communications for Aditxt, a long-time investor and advisor to the company.

Amro Albanna (01:03):

Great. And I think folks look as a public company,

and we are a young, small public company, but one of the things we want to do is to continue to provide updates about the company above

and beyond what we are required to do with public filings. We have many activities going on at the same time, whether it's Adimune,

Pearsanta, Adivue, couple other acquisitions, and we truly believe that the business model of Aditxt can only be successful if we can

engage stakeholders in the process of advancing these innovations.

So in case this is your first time and you're

wondering why we're having these weekly updates, this is something that we see as a critical tool for us to continue to broadcast

our message. You never know who's going to hear it. You never know who wants some update. You never know who's a current shareholder

or a future shareholder. And frankly, this is not only for shareholders.

I was up in Mountain View in our innovation

center a couple of days ago, and it was wonderful to hear a couple of our team members. They told me that they tune in. They

listened to the weekly updates, which is another tool to really communicate with all of our stakeholders, team members, partners,

vendors, shareholders, people with certain indications like psoriasis or Type 1 diabetes that are keenly interested in hearing the

progrefss that we're making in each innovation.

So this is what the weekly update is for. Some

of them are going to be shorter than others. Some of them are going to be longer than others. Some of them are going to be more interesting

and more engaging than others. They're just the nature of the business. But that said, we continue to be committed and I'm

going to ask Jeff probably towards the end to really share with everyone what we're pushing for beyond just the weekly updates.

I mean, communication is going to be key for us and Jeff is a veteran experienced communicator and it always helps to have his perspective.

So that said, Jeff, anything you want to add to

that and then I'll just give a quick overview of our business model, the various programs, and we'll take it from there.

Jeff Ramson (03:19):

The only thing I would say is, again, like I've

said before, I look at myself as an investor and I try to put myself in the shoes of investors and Aditxt. And so I think investors appreciate

the opportunity to have access to this kind of communication, right? And we'll talk later about other forms of communication and

other ways to get a message. But I do think it's great that you're doing these just to keep in front of everybody and let

them see the progress that you're making and the challenges.

Amro Albanna (03:48):

No, sorry, Jeff, go ahead.

Jeff Ramson (03:50):

And the challenges, right? I mean, it's

a very, very authentic communication.

Amro Albanna (03:54):

Look, I mean, there is no doubt that it is a challenging

market and I really never like to use the market as an excuse for something that's going on with our company. But reality is there

is a general challenge for the market and there has been a challenge in the last two to three years for the microcap companies. I mean,

that's just reality. And for the last couple years, three years, I mean, you can see some of the delisting that's going on.

You can see some of the bankruptcies that are going on. It has been a challenging period for microcap companies.

So that said, I got to go back to the core of

Aditxt. What is Aditxt? And you can probably... when we're talking about shareholders and investors, Jeff, just because you brought

that up, while we're talking about stakeholders, let's just address shareholders because I think that's really important.

From my point of view, there are truly investors, people that coming in and they want to have an ownership in the company because of the

vision of Aditxt and what we can accomplish as we move forward and there are traders.

I've always said I cannot and we cannot

run the company based on a trading strategy. If somebody buys today, the stock goes down tomorrow, that is not going to change the way

we operate the business. If somebody buys today and that stock goes up tomorrow, again, that is not the way we're going to run the

business. Ultimately, ultimately our business and I believe the success of our business will be determined whether or not we are successful

on delivering one or more of the innovations that we have. That is what Aditxt is all about.

You pick up an innovation, an asset, or a company.

You build it with the goal of positioning it for global growth. That is our business model. We started out with Adimune. Adimune, again,

for those that have not heard this before, when it comes to autoimmune diseases, it is caused by the fact that our immune system attacks

our own cells, our own tissues. That is psoriasis. That is Type 1 diabetes. There is multiple sclerosis, 80 to 100 different autoimmune

diseases that are caused by a condition where our immune system and instead of attacking external threats, it will also attack our own

And for the last 40, 50 years, generally speaking,

there has been some type of immunosuppressant to basically slow down the pace of that rejection. With Adimune, our approach is a fundamentally

different approach, which is the attempt to retrain the immune system to make it recognize that our tissues are our tissues and not to

be attacked and that is the fundamental difference. For the last four years, especially since we've been public, our team, innovation

team, operational team, legal team, finance team, every single one of the company, and you know, Jeff, you've been around even before

Our goal has been can we get Adimune and ADI into

human trials. That is the inflection point for Adimune. It's not about an office space. It's not about listing. It's

not about number of people. It's not about this or that. It is ultimately, we are here in this business to make sure to advance

ADI platform, starting with ADI platform, into human trials. Can we show... can we eventually get into human trials to attempt the retraining

of our immune system to see if we can address autoimmune diseases, starting with psoriasis and Type 1 diabetes in Germany and stiff person

syndrome with the Mayo Clinic here in the US. That's our goal.

And obviously, there are things that have to be

approved before we can continue. We have to have FDA approval. We have to have regulatory approval in Europe in order for us to be able

to do that. And our goal continues and remains to be entering human trials, at least filing for IND and CTA. CTA is clinical trial application

and then the IND for the FDA. Our goal is either Q3 or Q4, but 2025, and that progress continues.

Now, can we get into human trials by late this

year? That's still the goal and that is a significant progress by the team, especially for a company with limited resources and

we have been very resourceful. That's Adimune and we will continue to update our stakeholders of what's taking place. But

it is a major project and our success beginning with human trials and showing safety if we can and showing efficacy if we can. We cannot

guarantee biology, but that is the focus of Adimune.

Anything that I missed on Adimune, Jeff?

Jeff Ramson (08:40):

No, no, I think that's great.

Amro Albanna (08:42):

Okay. And that project, that subsidiary is called

Adimune and Dr. Friedrich Kapp is leading that subsidiary with full force and we could not have a better leader than Friedrich and supported

by our team members to lead that project.

So Pearsanta. Pearsanta, as we discussed, really

begins with early disease detection. And I actually see Chris, who's been here on the show before, on the weekly update before,

I see him joining. And Chris does a tremendous job articulating Pearsanta and the vision and the mission of Pearsanta.

So what is early disease detection? Ultimately,

we would say, let's take cancer as an example. We all believe that the best or the highest probability for treating cancer has to

begin with early detection. The earlier, the better. Again, general statement, the earlier, the better. But ultimately, the best treatment

for cancer is not to get it in the first place.

So Pearsanta with its existing technology is the